Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05838638 · ClinicalTrials.gov registry record · NA
Serious Gaming for Chemotherapy-induced Nausea and Vomiting
A NA study of Neoplasms and Chemotherapy-induced Nausea and Vomiting, sponsored by University of Central Florida.
- Recruiting
- Registry status
- NA
- Development phase
- 610
- Enrollment target
- 2
- Study locations
NCT05838638: Recruiting NA study of Neoplasms and Chemotherapy-induced Nausea and Vomiting, sponsored by University of Central Florida.
NCT05838638 is a NA study of Neoplasms and Chemotherapy-induced Nausea and Vomiting that is actively recruiting participants, run by University of Central Florida. The registered enrollment target is 610 participants, below the 1,617-participant average among 158 other Neoplasms trials with a reported enrollment target (62% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05838638, a NA study of Neoplasms and Chemotherapy-induced Nausea and Vomiting, is actively recruiting participants, sponsored by University of Central Florida.
- RECRUITING
- Registry status
- NA
- Development phase
- 610 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to examine the effectiveness of a technology-based intervention for managing nausea and vomiting in older adults with cancer. Participants will be randomized to either an intervention or control group. Outcomes such as symptom severity, quality of life, and resource use will be examined.
Primary Outcome
any emergency department or hospital admission will be recorded using a dichotomous variable (yes/no)
Conditions Studied
Interventions
- BEHAVIORAL eSSET-CINV
Study Locations (2)
Florida
- Miller School of Medicine Sylvester Comp. Cancer Center - Miami
- Orlando Health - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 610 participants |
| Start Date | 2023-06-09 |
| Est. Completion | 2027-06-30 |
| Phase | NA |
What NCT05838638 shows while recruiting
NCT05838638 is an interventional study that assigns participants to a tested intervention. The registered 610 participants enrollment target is mid-sized for trials with a published cap, below the 1,617-participant average among 158 other Neoplasms trials with a reported enrollment target (62% lower).
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which eSSET-CINV is the first listed.
NCT05838638 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT05838638 about?
NCT05838638 is a clinical study titled "Serious Gaming for Chemotherapy-induced Nausea and Vomiting". The purpose of this study is to examine the effectiveness of a technology-based intervention for managing nausea and vomiting in older adults with cancer. Participants will be randomized to either an intervention or control group. Outcomes such as symptom severity, quality of life, and resource use ...
What is the current status of trial NCT05838638?
This trial is currently recruiting. It is a NA study. The enrollment target is 610 participants. The study started on 2023-06-09. Estimated completion is 2027-06-30.
What conditions does trial NCT05838638 study?
This clinical trial studies the following conditions: Neoplasms, Chemotherapy-induced Nausea and Vomiting.
What interventions are being tested in trial NCT05838638?
The interventions under investigation include: eSSET-CINV (BEHAVIORAL).
Who is sponsoring clinical trial NCT05838638?
This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05838638 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05838638's enrollment target sits among peer trials
610 20th of 158 higher than 138 of 158 other Neoplasms trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Endometrial Cell Collection With the PadKit
RECRUITING · NA
-
Biennial CEM in Women With a Personal History of Breast Cancer
RECRUITING · NA
-
LITT Followed by Hypofractionated RT for Recurrent Gliomas
RECRUITING · NA
-
Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy
RECRUITING · NA
-
Screening Strategies Among High-risk Populations for Anal Cancer
RECRUITING · NA
-
Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03536312 · 610 participants · NA
Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance
- NCT07075718 · 610 participants · Phase 2
Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant
- NCT00823654 · 609 participants
Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations
- NCT04224493 · 612 participants · Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI